Clinical Trials Logo

Urinary Bladder Disease clinical trials

View clinical trials related to Urinary Bladder Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT03123055 Terminated - Clinical trials for Urinary Bladder Disease

A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

FIERCE-22
Start date: April 20, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2 multi-center, open-label study to establish the initial safety and to determine a recommended Phase 2 dose of B-701 in combination with pembrolizumab, and to determine safety, tolerability and efficacy of B-701 (vofatamab) plus pembrolizumab in the treatment of subjects with locally advanced or metastatic UCC, who have progressed following platinum-based chemotherapy and who have not received prior immune checkpoint inhibitor therapy.

NCT ID: NCT02401542 Terminated - Clinical trials for Urinary Bladder Disease

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

FIERCE-21
Start date: June 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2(b), sequential, dose escalation, open-label, randomized expansion, multicenter, efficacy and safety study of vofatamab alone or in combination with docetaxel, or versus docetaxel in FGFR3 mutant/fusion subjects with Stage IV, locally advanced or metastatic UCC who have relapsed after, or are refractory to at least one prior line of chemotherapy. This study is divided into 3 phases: Phase 1b (Cohort 1), Phase 2 (Cohorts 2 and 3), and Phase 2b (Monotherapy Expansion Phase and Randomized Phase).

NCT ID: NCT01613586 Completed - Pain Clinical Trials

A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)

AMARANTH
Start date: May 31, 2012
Phase: Phase 2
Study type: Interventional

In this study several dose levels of ASP3652, given orally for 12 weeks, will be compared with placebo in the treatment of female patients with Bladder Pain Syndrome / Interstitial Cystitis.